OBJECTIVE: We examined survival and prognostic factors of patients who developed HIV-associated non-Hodgkin lymphoma (NHL) in the era of combination antiretroviral therapy (cART). DESIGN AND SETTING: Multicohort collaboration of 33 European cohorts. METHODS: We included all cART-naive patients enrolled in cohorts participating in the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) who were aged 16 years or older, started cART at some point after 1 January 1998 and developed NHL after 1 January 1998. Patients had to have a CD4 cell count after 1 January 1998 and one at diagnosis of the NHL. Survival and prognostic factors were estimated using Weibull models, with random effects accounting for heterogeneity between cohorts. RESULTS: Of 67 659 patients who were followed up during 304 940 person-years, 1176 patients were diagnosed with NHL. Eight hundred and forty-seven patients (72%) from 22 cohorts met inclusion criteria. Survival at 1 year was 66% [95% confidence interval (CI) 63-70%] for systemic NHL (n = 763) and 54% (95% CI: 43-65%) for primary brain lymphoma (n = 84). Risk factors for death included low nadir CD4 cell counts and a history of injection drug use. Patients developing NHL on cART had an increased risk of death compared with patients who were cART naive at diagnosis. CONCLUSION: In the era of cART two-thirds of patients diagnosed with HIV-related systemic NHL survive for longer than 1 year after diagnosis. Survival is poorer in patients diagnosed with primary brain lymphoma. More advanced immunodeficiency is the dominant prognostic factor for mortality in patients with HIV-related NHL.
OBJECTIVE: We examined survival and prognostic factors of patients who developed HIV-associated non-Hodgkin lymphoma (NHL) in the era of combination antiretroviral therapy (cART). DESIGN AND SETTING: Multicohort collaboration of 33 European cohorts. METHODS: We included all cART-naive patients enrolled in cohorts participating in the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) who were aged 16 years or older, started cART at some point after 1 January 1998 and developed NHL after 1 January 1998. Patients had to have a CD4 cell count after 1 January 1998 and one at diagnosis of the NHL. Survival and prognostic factors were estimated using Weibull models, with random effects accounting for heterogeneity between cohorts. RESULTS: Of 67 659 patients who were followed up during 304 940 person-years, 1176 patients were diagnosed with NHL. Eight hundred and forty-seven patients (72%) from 22 cohorts met inclusion criteria. Survival at 1 year was 66% [95% confidence interval (CI) 63-70%] for systemic NHL (n = 763) and 54% (95% CI: 43-65%) for primary brain lymphoma (n = 84). Risk factors for death included low nadir CD4 cell counts and a history of injection drug use. Patients developing NHL on cART had an increased risk of death compared with patients who were cART naive at diagnosis. CONCLUSION: In the era of cART two-thirds of patients diagnosed with HIV-related systemic NHL survive for longer than 1 year after diagnosis. Survival is poorer in patients diagnosed with primary brain lymphoma. More advanced immunodeficiency is the dominant prognostic factor for mortality in patients with HIV-related NHL.
Authors: Stefan K Barta; Xiaonan Xue; Dan Wang; Jeannette Y Lee; Lawrence D Kaplan; Josep-Maria Ribera; Albert Oriol; Michele Spina; Umberto Tirelli; Francois Boue; Wyndham H Wilson; Christoph Wyen; Kieron Dunleavy; Ariela Noy; Joseph A Sparano Journal: Haematologica Date: 2014-08-22 Impact factor: 9.941
Authors: Jacqueline Neuhaus; Brian Angus; Justyna D Kowalska; Alberto La Rosa; Jim Sampson; Deborah Wentworth; Amanda Mocroft Journal: AIDS Date: 2010-03-13 Impact factor: 4.177
Authors: Emilie Lanoy; Philip S Rosenberg; Fabien Fily; Anne-Sophie Lascaux; Valerie Martinez; Maria Partisani; Isabelle Poizot-Martin; Elisabeth Rouveix; Eric A Engels; Dominique Costagliola; James J Goedert Journal: Blood Date: 2011-05-06 Impact factor: 22.113
Authors: Moses H Bateganya; Jeffrey Stanaway; Paula E Brentlinger; Amalia S Magaret; Anna Wald; Jackson Orem; Corey Casper Journal: J Acquir Immune Defic Syndr Date: 2011-04 Impact factor: 3.731
Authors: Chad J Achenbach; Stephen R Cole; Mari M Kitahata; Corey Casper; James H Willig; Michael J Mugavero; Michael S Saag Journal: AIDS Date: 2011-03-13 Impact factor: 4.177